However, as many as 40-50% of patients receiving this drug will develop oxaliplatin-induced peripheral neuropathy (OIPN) ( 2, 3). Oxaliplatin, a platinum-based anti-tumor agent, is a mainstay of treatment for many gastrointestinal cancers, particularly colorectal cancer, the second highest cause of cancer mortality worldwide ( 1).
#Random effects meta analysis registration
Systematic Review Registration:, Prospero Registration Number: CRD42021225095. Further research on ways to limit OIPN is needed. Of note is that most of these studies have focused on pharmacological interventions non-pharmacological interventions are underexplored. Of the 30 interventions examined, there were six interventions supporting potential efficacy, 11 interventions with insufficient evidence and 13 interventions not recommended.Ĭonclusion: Currently, there is insufficient certainty to support any intervention as effective in preventing OIPN. Ratings were assessed via a combination of outcomes with quality assessment using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. Results: Forty-four trials were analyzed describing 29 chemoprotective interventions, including combinations, and 1 non-pharmacological intervention. A network meta-analysis was conducted to derive indirect evidence of any preventive effect of an intervention against placebo when original trials compared one intervention against another. The pooled risk ratio and its 95% confidence interval were calculated using a random effects model. The primary outcome measure was the incidence of chronic OIPN with a preventive intervention as compared to placebo or no intervention. Methods: Literature databases PubMed-MEDLINE, Embase and Scopus, were searched from to and major conferences’ abstracts were reviewed for randomized controlled trials that examined the efficacy of any preventive measure for OIPN. A systematic review and meta-analysis were conducted to evaluate the existing pharmacological and non-pharmacological interventions to prevent chronic OIPN. Trials studying preventive measures have been inconclusive. 6Department of Radiation Oncology, National University Cancer Institute Singapore, National University Health System, Singapore, Singaporeīackground: Oxaliplatin-induced peripheral neuropathy (OIPN) has significant clinical impact on the quality of life for cancer patients and is a dose limiting toxicity.5Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.4The N.1 Institute for Health, National University of Singapore, Singapore, Singapore.3Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Health System, Singapore, Singapore.2Health Services and System Research, Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore.1Department of Medicine, National University Health System, Singapore, Singapore.Siyu Peng 1† Ariel Fangting Ying 2† Nicholas Jian Hao Chan 1 Raghav Sundar 3,4,5 Yu Yang Soon 6* Aishwarya Bandla 3,4*
0 kommentar(er)
